Please ensure Javascript is enabled for purposes of website accessibility

McKesson Still Wants Moore

By W.D. Crotty – Updated Nov 16, 2016 at 5:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Moore Medical loses a suitor, but has a sturdy backup plan.

Friday the 13th bore evil tidings for bride-to-be Moore Medical (AMEX:MMD), a surgical and pharmaceutical products specialist. Settle in for a tale of courtship, betrayal, and redemption.

On Jan. 20, Moore announced that it would be acquired by drug wholesaler McKesson (NYSE:MCK) for $12 a share. Unable to forever hold its peace, SJ Strategic Investments the very next day offered $15 a share. Today, when that deal fell through, Moore plunged 14%, illustrating the risk involved in betting on merger and acquisition (M&A) outcomes.

Business news has been dominated lately by Comcast's (NASDAQ:CMCSA) bid for Disney (NYSE:DIS). Disney, which failed to hold above $25 after breaching it in mid-January, now trades above both $27 and the value of Comcast's original all-stock offer. Obviously there is speculation that either Comcast will up its offer or that other bidders will emerge.

As a rule, once a solid offer is made there's a good chance merger partners will get together. Pfizer (NYSE:PFE), for example, offered a 54% premium for Esperion some months back -- and that merger recently closed.

The Comcast play for Disney is different, however, in that it is a hostile one. That is, Disney did not exactly encourage the overtures. But ask for it or not, it suddenly finds itself "in play," which is Wall Street jargon for "bleeding in shark-infested waters."

Disney shareholders must be dreaming of what could be. Might General Electric (NYSE:GE) get creative with other bidding partners so it could at least get its hands on the theme parks and other entertainment assets? Has Bill Gates directed Microsoft (NASDAQ:MSFT) to accumulate $52 billion in cash just so he could make a mostly cash offer? Sounds nutty, but it is dreams that will keep Disney's stock price inflated, at least for now. As always, inflation can turn to deflation if management manages to fend off all partners.

OK, right -- back to Moore Medical. Does the left-at-the-altar bride have a dandy-in-waiting? Yes! Turns out McKesson, true to its word, will indeed acquire all the outstanding stock at the original offer of $12. It's not $15, but it is a 54.4% premium over the stock's average close over the last 30 days.

It could have been a lot worse. As usual, a failed merger led to a fall in price. Fortunately, Moore has fallen, but it can get up.

W.D. Crotty is a shareholder in Disney and is watching the merger news with great interest. He and other investors actively discuss Disney on The Motley Fool's discussion boards. For a 30-day free trial to the discussion boards, click here.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

The Walt Disney Company Stock Quote
The Walt Disney Company
DIS
$99.50 (-2.60%) $-2.66
Comcast Corporation Stock Quote
Comcast Corporation
CMCSA
$31.84 (-1.94%) $0.63
Microsoft Corporation Stock Quote
Microsoft Corporation
MSFT
$237.92 (-1.27%) $-3.06
General Electric Company Stock Quote
General Electric Company
GE
$64.55 (-1.24%) $0.81
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$44.08 (-1.10%) $0.49
McKesson Corporation Stock Quote
McKesson Corporation
MCK
$343.27 (-1.06%) $-3.69

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.